Health
Eli Lilly’s Oral Pill Shows Strong Weight Loss Results in Clinical Trials
Eli Lilly’s new oral pill, orforglipron, has demonstrated up to 8% weight loss in clinical trials, outperforming existing oral semaglutide alternatives. The results signal growing competition in the weight-loss drug market, where demand for convenient and effective treatments continues to rise.
The trial, published in The Lancet, involved more than 1,600 participants with type 2 diabetes across over 130 research centres in five countries. Participants were assigned to different doses of orforglipron, ranging from 12mg to 36mg, or equivalent doses of oral semaglutide for one year.
Results showed that roughly 60% of those taking orforglipron lost at least 5% of their body weight, compared with 40% of participants on semaglutide. Between 28% and 44% of patients on orforglipron lost 10% or more, while only 13% to 21% of those on semaglutide reached similar reductions. Participants also experienced improved blood sugar control, with orforglipron lowering glucose levels more effectively than its competitor.
Experts welcomed the results but urged caution. Naveed Sattar, professor of cardiometabolic medicine at the University of Glasgow, said oral medications that help patients lose weight and maintain it are vital, noting that excess weight is a key driver of type 2 diabetes and associated cardiovascular risks. Marie Spreckley, a weight management researcher at Cambridge University, highlighted that while the trial showed benefits, side effects and long-term safety remain important considerations.
Adverse effects were more common among orforglipron users. Approximately 9-10% of participants stopped the treatment due to gastrointestinal issues, compared with about 5% of those on semaglutide. Spreckley noted that these effects could affect real-world tolerability outside the trial environment and called for further research on long-term outcomes, including cardiovascular health and sustained effectiveness.
Orforglipron is designed as a daily pill that does not require food or water restrictions, offering a more convenient alternative to injectable treatments such as Ozempic, Wegovy, and Mounjaro. Eli Lilly, which also markets Zepbound and Mounjaro, is positioning orforglipron as a competitor to Novo Nordisk, the current provider of the only approved oral GLP-1 pill.
The pill is under review by the US Food and Drug Administration. If approved, Eli Lilly said US patients with obesity could access the drug starting at $149 (€125.92) for the lowest dose, with higher doses priced up to $399 (€337) if insurance does not cover the cost.
As pharmaceutical companies race to make weight-loss treatments more accessible, orforglipron’s strong results highlight the potential of oral GLP-1 therapies to reshape the market, even as questions about side effects and long-term safety remain.
Health
Global Mental Health Cases Near 1.2 Billion as Anxiety and Depression Drive Sharp Worldwide Rise
A major global analysis has found that mental health conditions have surged to an estimated 1.2 billion people worldwide, driven largely by steep increases in anxiety and depression over the past three decades.
The findings, published in The Lancet as part of the Global Burden of Disease Study 2023, show that the number of people living with mental disorders has almost doubled since 1990, marking a 95% rise. Researchers say major depressive disorder and anxiety disorders have seen even sharper growth, increasing by 131% and 158% respectively, making them the most prevalent mental health conditions globally.
The report describes mental illnesses as widespread conditions that create long-term disability and significant human suffering. It also highlights broader consequences for economies and public services, including reduced productivity, lower workforce participation and increasing pressure on health and welfare systems.
Researchers estimate that in 2023 alone, around 620 million females and 552 million males were affected by mental health conditions. While the overall burden is rising across both sexes, the study points to notable differences in the types and prevalence of disorders.
Among women, depression and anxiety were the most commonly reported conditions, alongside higher rates of eating disorders such as anorexia nervosa and bulimia nervosa. The report links this disparity to a mix of biological, social and structural factors, including exposure to domestic violence, sexual abuse, gender inequality and reproductive health-related changes.
In contrast, neurodevelopmental and behavioural disorders, including attention deficit hyperactivity disorder (ADHD), conduct disorder and autism spectrum conditions, were more frequently diagnosed in men.
Teenagers aged 15 to 19 were identified as the group experiencing the highest mental health burden globally, raising concerns about early onset of conditions and insufficient preventive care for young people.
The study identifies several key risk factors associated with mental illness, including childhood sexual violence, bullying and intimate partner violence. These factors are strongly linked to conditions such as depression, schizophrenia, bipolar disorder and anxiety disorders. However, researchers note that such exposures have remained relatively stable over time and account for only a portion of the overall rise.
According to the authors, broader drivers are likely contributing to the increasing prevalence of mental disorders. These include genetic and biological influences, poverty, inequality, and the growing impact of global crises such as armed conflict, pandemics, natural disasters and climate-related stress.
While mental health conditions have long been a leading cause of disability worldwide, the report warns that the situation is worsening. At the same time, health systems have not expanded services at a pace matching demand.
The authors caution that the gap between rising need and limited access to care is becoming more pronounced, leaving millions without adequate treatment or support.
Health
Europe Records Sharp Rise in Sexually Transmitted Infections, ECDC Warns
Health
White House Rejects Report It Blocked Return of Ebola-Infected US Doctor
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Home Improvement1 year agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
